Principal Securities, Inc. Biotechnology

Principal Securities, Inc.

$5.32 Trillion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NTLA Intellia Therapeutics, Inc.	$825M	$1.79 Million 0.0% of portfolio	191	Q2 2025 Added 114.61%
BBIO Bridge Bio Pharma, Inc.	$7.28B	$1.64 Million 0.0% of portfolio	38	Q3 2024 Reduced 73.05%
CVAC Cure Vac N.V.	$1.03B	$1.58 Million 0.0% of portfolio	291	Q3 2024 Added 64.41%
EDIT Editas Medicine, Inc.	$157M	$1.49 Million 0.0% of portfolio	678	Q2 2025 Added 176.73%
KRYS Krystal Biotech, Inc.	$3.69B	$1.38 Million 0.0% of portfolio	10	Q2 2025 Added 42.86%
ASND Ascendis Pharma A/S	$10.9B	$1.21 Million 0.0% of portfolio	7	Q2 2025 Added 16.67%
HLVX Hille Vax, Inc.	$69.5M	$1.19 Million 0.0% of portfolio	600	Q2 2025 Reduced 20.21%
VKTX Viking Therapeutics, Inc.	$3.06B	$1.03 Million 0.0% of portfolio	39	Q2 2025 Reduced 88.6%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.88B	$853,000 0.0% of portfolio	54	Q2 2025 Added 170.0%
KROS Keros Therapeutics, Inc.	$353M	$788,000 0.0% of portfolio	59	Q2 2025 New
ARDX Ardelyx, Inc.	$866M	$784,000 0.0% of portfolio	200	Q2 2025 New
ADMA Adma Biologics, Inc.	$3.29B	$747,000 0.0% of portfolio	41	Q2 2025 Added 86.36%
ARCT Arcturus Therapeutics Holdings Inc.	$396M	$716,000 0.0% of portfolio	55	Q2 2024 Reduced 15.38%
ABUS Arbutus Biopharma Corp	$510M	$711,000 0.0% of portfolio	230	Q4 2024 New
MRUS Merus N.V.	$2.93B	$684,000 0.0% of portfolio	13	Q2 2025 Added 85.71%
CRBU Caribou Biosciences, Inc.	$109M	$576,000 0.0% of portfolio	457	Q2 2025 Reduced 52.25%
ATAI Atai Life Sciences N.V.	$685M	$502,000 0.0% of portfolio	229	Q2 2025 New
RGNX Regenxbio Inc.	$350M	$484,000 0.0% of portfolio	59	Q2 2025 Reduced 68.78%
ARVN Arvinas, Inc.	$361M	$427,000 0.0% of portfolio	58	Q2 2025 New
MLTX Moon Lake Immunotherapeutics	$2.04B	$378,000 0.0% of portfolio	8	Q2 2025 New
WVE Wave Life Sciences Ltd.	$734M	$377,000 0.0% of portfolio	58	Q4 2024 Added 28.89%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$376,000 0.0% of portfolio	8	Q2 2025 Reduced 93.98%
EWTX Edgewise Therapeutics, Inc.	$846M	$354,000 0.0% of portfolio	27	Q3 2024 New
SRRK Scholar Rock Holding Corp	$1.66B	$319,000 0.0% of portfolio	9	Q2 2025 Added 125.0%
SBTX Silverback Therapeutics, Inc.	$0	$297,000 0.0% of portfolio	17	Q2 2025 New
CLLS Cellectis S.A.	$121M	$273,000 0.0% of portfolio	179	Q2 2025 Added 244.23%
REPL Replimune Group, Inc.	$259M	$242,000 0.0% of portfolio	26	Q2 2025 New
CNTA Centessa Pharmaceuticals PLC	$1.61B	$223,000 0.0% of portfolio	17	Q2 2025 New
KYMR Kymera Therapeutics, Inc.	$2.18B	$218,000 0.0% of portfolio	5	Q2 2025 New
MREO Mereo Biopharma Group PLC	$207M	$203,000 0.0% of portfolio	75	Q2 2025 Added 134.38%
ALT Altimmune, Inc.	$177M	$135,000 0.0% of portfolio	35	Q2 2025 New
VRDN Viridian Therapeutics, Inc.\De	$717M	$126,000 0.0% of portfolio	9	Q4 2024 New
BCYC Bicycle Therapeutics PLC	$214M	$125,000 0.0% of portfolio	18	Q2 2025 New
SLN Silence Therapeutics PLC	$201M	$99,000 0.0% of portfolio	17	Q2 2025 New
IMMP Immutep LTD	$147M	$95,000 0.0% of portfolio	58	Q2 2025 New
GNFT Genfit S.A.	$189M	$89,000 0.0% of portfolio	24	Q2 2025 New
AUTL Autolus Therapeutics PLC	$195M	$84,000 0.0% of portfolio	37	Q2 2025 New
IPHA Innate Pharma Sa	$165M	$82,000 0.0% of portfolio	45	Q2 2025 New
SAVA Cassava Sciences Inc	$93M	$45,000 0.0% of portfolio	25	Q4 2024 Reduced 50.0%
HUMA Humacyte, Inc.	$185M	$31,000 0.0% of portfolio	15	Q2 2025 Reduced 94.0%
NTRB Nutri Band Inc.	$53.1M	$0 0.0% of portfolio	0	Q2 2025 Sold Out

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Principal Securities, Inc. with notifications on news.